<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The longitudinal analysis of the adult population of Framingham, Massachusetts has clarified the pivotal role of <z:hpo ids='HP_0000822'>hypertension</z:hpo> in the epidemiology of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> incidence increases in men and women as arterial blood pressure, either systolic or diastolic, increases </plain></SENT>
<SENT sid="2" pm="."><plain>Isolated systolic <z:hpo ids='HP_0000822'>hypertension</z:hpo> increases the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> in the elderly </plain></SENT>
<SENT sid="3" pm="."><plain>Successful <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy decreases <z:hpo ids='HP_0001297'>stroke</z:hpo> incidence in asymptomatic persons, hypertensive patients with <z:hpo ids='HP_0002326'>transient ischemic attacks</z:hpo> and survivors of hypertensive <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A stepped care approach to <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy utilizing <z:chebi fb="40" ids="35498">diuretic</z:chebi> drugs, antiadrenergic agents and <z:chebi fb="1" ids="35620">vasodilators</z:chebi> is well tolerated in the vast majority of patients with established cerebrovascular disease </plain></SENT>
<SENT sid="5" pm="."><plain>Agents with a propensity to cause <z:hpo ids='HP_0001278'>orthostatic hypotension</z:hpo> should be avoided </plain></SENT>
<SENT sid="6" pm="."><plain>Reduction of blood pressure should be gradual with dose increments at intervals of 6 to 8 weeks </plain></SENT>
<SENT sid="7" pm="."><plain>Mild <z:hpo ids='HP_0000822'>hypertension</z:hpo> may be left untreated during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of atherothrombotic <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A trial of blood pressure reduction with <z:chebi fb="0" ids="29321">sodium nitroprusside</z:chebi> to normotensive or mildly hypotensive levels is indicated in patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>If <z:hpo ids='HP_0002344'>neurologic deterioration</z:hpo> occurs, the infusion rate of <z:chebi fb="0" ids="29321">sodium nitroprusside</z:chebi> can be reduced and blood pressure will rapidly rise </plain></SENT>
<SENT sid="10" pm="."><plain>Successful management of <z:hpo ids='HP_0000822'>hypertension</z:hpo> has undoubtedly contributed to the decreasing <z:hpo ids='HP_0011420'>death</z:hpo> rate from <z:hpo ids='HP_0001297'>stroke</z:hpo> in the United States </plain></SENT>
</text></document>